DPP4

(redirected from Dipeptidyl Peptidase IV)
Also found in: Acronyms.

DPP4

A gene on chromosome 2q24.3 that encodes dipeptidyl-peptidase 4, a ubiquitous, membrane-bound enzyme with roles in nutrition, metabolism, the endocrine system, immune regulation (for instance, it is essential for T-cell receptor (TCR)-mediated T-cell activation), bone marrow mobilisation, apoptosis, cell adhesion and tumourigenesis.
References in periodicals archive ?
Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes.
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
For example, some regulatory peptides are metabolized/ modulated by membrane-bound peptidases such as dipeptidyl peptidase IV (DPPIV or CD26) and angiotensin-converting enzyme (22-25).
In addition to mimicking the effects of GLP-1, the compounds being tested also resist the enzyme dipeptidyl peptidase IV (DPP-IV), which naturally inactivates GLP-1.
Alogliptin is a dipeptidyl peptidase IV or DPP-4 inhibitor being investigated as an adjunct to diet and exercise for the treatment of Type 2 diabetes.
TOKYO:4503)("Astellas") announced today that Prosidion's patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of USD 609 million.
Chapter 12: Dipeptidyl peptidase IV inhibitors for treatment of diabetes (McIntosh, CHS, Kim, S-J.
rights to potential future regulatory and sales-based milestones and, if approved, royalties on sales for Takeda Pharmaceutical Company Limited's dipeptidyl peptidase IV (DPP-4) inhibitor, alogliptin, for which the FDA issued a complete response letter in June 2009 and requested Takeda conduct an additional cardiovascular safety trial to satisfy the FDA's December 2008 guidance on anti-diabetic therapies;
PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Alogliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor discovered by Takeda's wholly-owned U.

Full browser ?